Background: Clinicians managing patients receiving the direct thrombin inhibitor dabigatran
may benefit in being able to determine the amount of drug present in selected situations …

Introduction The knowledge of dabigatran levels is helpful for decision‐making in specific
situations such as urgent surgery or when the question of reversal arises (uncontrolled …

Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for
prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate …

Context. Dabigatran etexilate is one of the newer oral anticoagulants and a direct thrombin
inhibitor. Concerns regarding dabigatran's use include its lack of validated laboratory …

Aims In patients with atrial fibrillation prescribed dabigatran, the aim was to examine the
correlation between plasma dabigatran concentrations and the three screening coagulation …

Patients with atrial fibrillation requiring maintenance haemodialysis are at increased risk of
ischaemic stroke and bleeds. Currently, vitamin K antagonists such as warfarin are …

Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …

Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various
thromboembolic complications. An advantage of this agent over other anticoagulants is that …

OBJECTIVE The objective of this assay validation study was to determine whether the
Hemoclot® Thrombin Inhibitor Assay [ACK002K, HYPHEN BioMed, France] is suitable for …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Dabigatran etexilate is an oral
prodrug that is rapidly converted to dabigatran, a direct and reversible thrombin inhibitor.• …